

Press Release

Stockholm, Sweden, October 8, 2024

Mendus announces industry conference participation in October-November

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will participate in the following upcoming industry and investor conferences in the period October-November 2024:

LSX Nordic conference

Copenhagen, Denmark, October 8-9

Mendus CEO Erik Manting will hold a company Showcase presentation on October 9, 11.00 CET. Dr Manting will also participate in a panel discussion titled "ATMPs and a New Paradigm Shift for Patients: Initiatives and Ambitions in the Nordics" on October 9, 14.50 CET. The panel focuses on how new advanced therapies (ATMPs) offer life-changing potential for many patients who battle with serious rare diseases and cancers. Mendus has entered into an ATMP manufacturing alliance with NorthX Biologics, to enable large-scale manufacturing of its lead product, vididencel.

[Biotech, Healthtech & Medtech Investment | LSX Nordic Congress \(informaconnect.com\)](https://informaconnect.com)

CONDOR Symposium

Bordeaux, France, October 10-11

Mendus CMO Jeroen Rovers will participate in the annual symposium of the Precision Medicine and Immunotherapy of Sarcoma (CONDOR) program, held at Institut Bergonié, Bordeaux, France. Together with Institut Bergonié, Mendus is preparing to study the intratumoral primer ilixadencel in combination with regorafenib and avelumab as a novel treatment for soft tissue sarcoma as part of the REGOMUNE trial. See our July 23 press release of for more background [Mendus announces collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas - Mendus](#). For more information on the CONDOR program, please visit [HOME - CONDOR PROGRAM - Therapeutic Management of STS](#)

[EVENTS & MEETINGS - CONDOR PROGRAM - Management of STS](#)

BioEurope

Stockholm, Sweden, November 4-6

Mendus CEO Erik Manting will participate for investor and industry meetings.

[BIO-Europe | Meet dealmakers from biotech, pharma and finance \(informaconnect.com\)](https://informaconnect.com)

SITC 2024

Houston, Texas, USA, November 6-10

On November 8, Mendus will present preclinical data supporting the combination of its intratumoral primer ilixadencel with the immune checkpoint inhibitor avelumab at the 39th annual meeting of the Society for Immunotherapy of Cancer (SITC). SITC abstract titles are available via [Titles and Publications - SITC 2024 \(sitcancer.org\)](#), abstract number is 761. Together with Institut Bergonié,

Mendus is preparing study ilixadencel in combination with avelumab and the tyrosine kinase inhibitor regorafenib in soft tissue sarcoma, as part of the REGOMUNE trial.

[Home - SITC 2024 \(sitcancer.org\)](https://sitcancer.org)

ALLG Scientific Meeting

Melbourne, Australia, November 12-15

Mendus CMO Jeroen Rovers will participate in the biannual investigator meeting organized by the Australasian Leukaemia and Lymphoma Group (ALLG). Together with ALLG, Mendus will study its lead program vididencel as a novel maintenance therapy for acute myeloid leukemia (AML) in combination with oral azacitidine (aza) in the AMLM22-CADENCE trial. Mendus and ALLG are in the process of opening up to 9 clinical centres in 2024Q4 to support the first stage of the trial, which comprises 40 patients to study the safety of the vididencel + oral aza combination. This stage will be followed by another 100 patients to study efficacy of the combination versus oral aza, currently the only approved AML maintenance drug.

[November 2024 Scientific Meeting | The Australasian Leukaemia and Lymphoma Group \(allg.org.au\)](https://allg.org.au)

Jefferies Healthcare Conference

London, UK, November 19-21

Mendus CEO Erik Manting will participate for investor and industry meetings.

[Jefferies Global Healthcare Conference 2024 | Jefferies.com](https://jefferies.com)

For more information, please contact:

Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>